The Cigna Group 2026 UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. I think we'll go ahead and get started. Welcome everybody to our next session. We're really pleased to have The Cigna Group with us again this year. Ann Dennison, EVP and Chief Financial Officer. Thanks so much, Ann, for doing this again. The company had a recent Investor Day, positioned Cigna as a leader in complex care and healthcare personalization, and highlighted the combined capabilities of Evernorth and Cigna Healthcare to get you there. The business model was discussed, the combined significant. The business model was combined with a significant discussion around a modernization initiative. Looking at the 2030 targets that you laid out at Investor Day, what will be meaningfully different about Cigna's earnings mix by that timeframe? Which business or capabilities do you expect to become much more important?
Sure. First, let me just say thank you for having us here today. Great to be here, just on the back of earnings and on the back of our Investor Day. Look forward to the conversation. Appreciate you having us. With respect to our business, maybe I would like to just start by saying, we talked a lot at Investor Day about our Lead to One strategy and how important it is, the personalization and our ability to serve those with the most complex conditions. When you think about our portfolio of businesses that we've deliberately shaped over the last decade plus, we've positioned ourselves really well to serve those areas of need. If I'm just kind of walking down the businesses, the specialty business, which is about 37% of our overall earnings, it's 100% serving the needs of complex care.
That business, growing 8%-12%, it's our highest growing business. Then you've got our Cigna Healthcare business, 40% of our business. 55% of that business is serving complex care patients. Then pharmacy benefit services, 70% of 23% of our earnings, and 70% of it goes to serving complex care. With respect to your question in terms of what, looking forward, what's going to look different about the business, we would expect that the specialty business, given that it's the highest growing business, will become a bigger and bigger portion of our overall earnings, and will be about 40% as we look out into 2030. That, coupled with the investments we've made across each of the businesses to serve the complex populations, has positioned us well to achieve our long-term objective of 10%-14%.
In addition to that, and you referenced in the question as well, our Accelerate to One program. It's got a $3 billion gross run rate savings objective, productivity and modernization. Not all of it's going to fall to the bottom line, but certainly, we're going to reinvest some of it into the business to drive growth, and some of it's going to fall to the bottom line. Hitting our growth rates, achieving our objectives around Accelerate to One, those things we expect to be true and will support our 10%-14% growth over the long term.
No, that is great. To what extent are those long-term earnings targets dependent upon just the market continuing sort of at its current pace, or are you assuming your relative market performance is going to be better than the underlying market dynamics? Maybe what is some of that to get to $45 in 2030?
Sure. When you think about this, our three deliberately shaped portfolio of three businesses, there are three things that we talked about at Investor Day and that we keep pointing to. There are three elements to delivering. One is core growth, two is our distinct capabilities that we have in each of our business that help add to the equation, and then execution. We have to hit on all of those three levers to deliver over time. If you think about specialty and care, 8%-12% growth in specialty and care, some of that will come from secular growth and some of that will come from us, sorry, us as a leader in the market. Same thing for each of our businesses.
Okay. I think you have got a range effectively, 10%-14%. The underlying growth seems like it gets you pretty close to the low end, coupled with your capital deployment priorities, gets you pretty close to that low end. Is that a fair way to think about it, or?
The low end is not our target. We had talked about at Investor Day that we would expect to be at a minimum of $45 of EPS.
Right by 2030. That assumes we hit the low end of every Right range across all of our businesses.
An important thing to note there is we're not relying on any one business to get there.
Right. And so- Two ways to look at it.
Two ways to look at it.
One is that you got a lot of hedges naturally that say I can get to that low end 10% growth, which is not bad growth in and of itself. The other way is, the market momentum in most of your businesses, I think, would carry you pretty close to that unless there's some big sea change in the market. You think that's a fair way to look at it?
I think that's a fair way to look at it. I think that the market momentum, plus our distinct capabilities, give us a clear pathway to achieving the 10%-14%, including our capital, the 4%-5% that we expect to get from capital deployment, so 6%-9% from our earnings growth.
Right. We feel really confident in that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
